1.84
price down icon0.54%   -0.01
pre-market  Vorhandelsmarkt:  1.92   0.08   +4.35%
loading
Schlusskurs vom Vortag:
$1.85
Offen:
$1.84
24-Stunden-Volumen:
2.48M
Relative Volume:
0.83
Marktkapitalisierung:
$183.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.34M
KGV:
-1.3529
EPS:
-1.36
Netto-Cashflow:
$-36.91M
1W Leistung:
-3.16%
1M Leistung:
+19.48%
6M Leistung:
+61.40%
1J Leistung:
+54.62%
1-Tages-Spanne:
Value
$1.76
$1.87
1-Wochen-Bereich:
Value
$1.76
$1.96
52-Wochen-Spanne:
Value
$0.772
$2.2691

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name
Firmenname
Sellas Life Sciences Group Inc
Name
Telefon
(646) 200-5278
Name
Adresse
7 TIMES SQUARE, NEW YORK, NY
Name
Mitarbeiter
15
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
SLS's Discussions on Twitter

Vergleichen Sie SLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SLS
Sellas Life Sciences Group Inc
1.84 189.58M 0 -37.34M -36.91M -1.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-07-21 Eingeleitet Cantor Fitzgerald Overweight
2018-11-01 Eingeleitet Oppenheimer Outperform
2018-04-02 Eingeleitet H.C. Wainwright Buy
2018-03-19 Hochstufung Maxim Group Hold → Buy

Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about SELLAS Life Sciences Group Inc. stockDynamic capital growth - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

What drives SELLAS Life Sciences Group Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is SELLAS Life Sciences Group Inc. a good long term investmentFree Bull & Bear Market Updates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

SELLAS Life Sciences Group Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

What makes SELLAS Life Sciences Group Inc. stock attractive to long term investorsMomentum Swing Watchlist - beatles.ru

Jul 20, 2025
pulisher
Jul 18, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Expected to Rise, Maxim Group Analyst Says - Defense World

Jul 18, 2025
pulisher
Jul 16, 2025

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Finansavisen

Jul 16, 2025
pulisher
Jul 16, 2025

Sellas Life Sciences shares fall 1.58% premarket after meeting primary endpoints in Phase 2 trial. - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of - GlobeNewswire

Jul 16, 2025
pulisher
Jul 15, 2025

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

What makes SELLAS Life Sciences Group Inc. stock price move sharplyReal Time Breakout Tracking - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How SELLAS Life Sciences Group Inc. stock performs during market volatilityHigh Yield Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Sellas Flat on Trial Success - Baystreet.ca

Jul 15, 2025
pulisher
Jul 15, 2025

Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS gains on mid-stage trial win for leukemia drug (SLS) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS' Phase 2 Study Of SLS009 In Acute Myeloid Leukemia Meets All Primary Goals - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Why SELLAS Life Sciences Group Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study - The Manila Times

Jul 15, 2025
pulisher
Jul 10, 2025

SELLAS Life Sciences Soars 14.21% on Key Appointment - AInvest

Jul 10, 2025
pulisher
Jul 09, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Market Movement, Down and Up - investchronicle.com

Jul 09, 2025
pulisher
Jul 09, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% – Here’s What Happened - Defense World

Jul 09, 2025
pulisher
Jul 07, 2025

SELLAS Life Sciences adds cancer research expert to scientific board By Investing.com - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board - citybiz

Jul 07, 2025
pulisher
Jul 07, 2025

SELLAS Life Sciences adds cancer research expert to scientific board - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

Cancer Research Leader from MD Anderson Strengthens SELLAS Scientific Board Ahead of Key Milestones - Stock Titan

Jul 07, 2025
pulisher
Jun 30, 2025

SELLAS Life Sciences Group, Inc.(NasdaqCM: SLS) added to Russell 2500 Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 24, 2025

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices - The Globe and Mail

Jun 24, 2025
pulisher
Jun 20, 2025

We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully - Yahoo Finance

Jun 20, 2025

Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):